Introduction {#sec1}
============

Age-related macular degeneration (AMD) is a leading cause of blindness in individuals 50 years and older in the United States and Europe.[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6] In 2010, an estimated 2.07 million people were living with AMD in the US with a projected 3.7 million by 2030.[@bib7] AMD severity is typically classified according to the Age-Related Eye Disease Study (AREDS) AMD Categories 1 through 4,[@bib8] dependent on drusen size and area, pigment epithelia state, geographic atrophy and neovascularization. There are two advanced forms of AMD (AREDS Category 4) -- geographic atrophy (GA) and neovascular AMD (nAMD) characterized by choroidal neovascularization (CNV),[@bib9] ^,^ [@bib10] more recently termed macular neovascularization.[@bib11] nAMD occurs in 10-15% of all AMD cases and causes an estimated 80% of severe vision loss attributable to AMD.[@bib2] ^,^ [@bib10] ^,^ [@bib12] Typically, both forms are preceded by AREDS category 3 AMD, intermediate dry AMD (iAMD), characterized by numerous intermediate sized drusen, large drusen, and geographic atrophy.

Although aging is the most significant risk factor for development of AMD, modifiable risk factors have also been shown to influence the risk of progression from iAMD to advanced AMD.[@bib9] For example, smoking cessation and optimized cardiovascular risk factors have been correlated with reduced risk of developing advanced AMD.[@bib13], [@bib14], [@bib15], [@bib16], [@bib17] Additionally, the AREDS reported beneficial effects associated with consumption of a specific combination of supplements.[@bib8] ^,^ [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23] Nevertheless, there is no known treatment for iAMD. Upon detection of conversion to nAMD, standard-of-care includes intravitreal injections of anti-vascular endothelial growth factor-A (anti-VEGF) agents.[@bib24], [@bib25], [@bib26] Multiple studies have demonstrated that better visual acuity (VA) at the time of initiation of nAMD treatment and decreased time between onset of visual symptoms and treatment initiation are positively correlated with better absolute long-term VA outcomes,[@bib27] ^,^ [@bib28] highlighting the value of early diagnosis and treatment of nAMD.

Historically, monitoring of iAMD patients at risk of conversion included regular in-office examinations in addition to patient reporting of changes in visual symptoms.[@bib9] For monitoring between office visits, patients are advised to use the Amsler grid, a simple pattern of lines in order to detect scotomas or metamorphopsia, introduced by Marc Amsler in 1947[@bib29] ^,^ [@bib30] and validated by the Macular Photocoagulation Study Group.[@bib31] Although this is still a widely used method of self-monitoring, it has shown low levels of sensitivity and poor patient compliance.[@bib32] ^,^ [@bib33] More recent technology, however, has shown promise in the use of daily home telemonitoring of iAMD.

In 2014, the HOME study reported beneficial results from a randomized trial using the ForeseeHome device (Notal Vision Ltd, Tel Aviv, Israel) for early detection of conversion to nAMD.[@bib34] ^,^ [@bib35] ForeseeHome is a home monitoring device that patients use daily for 3 minutes per eye; after establishing a baseline, it monitors for changes in vision suggestive of CNV development.[@bib36] Change in visual function is measured through use of preferential hyperacuity perimetry to detect metamorphopsia or scotoma, and results in an alert sent to the patient's physician and the patient so a clinical appointment can be made to evaluate for signs of exudative disease activity. The main outcome measure of the HOME trial was the change in VA from baseline to detection of CNV between two arms: one monitored with standard of care only and another monitored with standard of care plus device usage. At the time of CNV detection, the device arm had a statistically significantly smaller decline in median VA than the standard care arm, at -4 and -9 letters, respectively. Furthermore, the device arm ultimately had an increased proportion of patients who maintained VA of 20/40 or better, at 87% compared to 62%. Based on these results, the authors concluded that patients at high risk of developing CNV would benefit from usage of the ForeseeHome device through increased likelihood of ultimate better VA outcomes. The HOME trial also reported good overall compliance of ForeseeHome use by participants and that performance of the device added minimal burden to patients with an annual false-positive alert rate of 0.24 per year, extrapolating this to one false alert every 4.2 years of device use.[@bib34]

The purpose of the current analysis was to determine the compliance of patients prescribed use of the ForeseeHome device and to describe real-world clinical experience with this home monitoring system in 4 large retina practices across the USA.

Methods {#sec2}
=======

Demographic and clinical information was retrospectively collected from 4 geographically distinct retina practices across the United States (Ophthalmic Consultants of Long Island, New York City, NY; Retina Consultants of Houston, Houston, TX; University Retina and Macula Associates, Chicago, IL; Retina Vitreous Associates of Florida, Tampa, FL). Institutional Review Board (IRB)/Ethics Committee approval was obtained for the study of patients in this Health Insurance Portability and Accountability Act (HIPAA)-compliant study adhering to the tenets of the Declaration of Helsinki. Date range of data collection was July 25, 2013 to January 3, 2020.

Metrics Collected {#sec2.1}
-----------------

For each patient, the eye prescribed, age at first use, length of use, days since last exam, total number of tests, ability to establish baseline, alert number and alert types were collected from the ForeseeHome portal ([www.foreseehomeonline.com](http://www.foreseehomeonline.com/){#intref0015}). Eyes were considered "active" if they had a test within 30 days of January 3, 2020. Eyes classified as "never used" included eyes that never filled their prescription and eyes that filled their prescription but never used the device. Overall frequency of use over total length of use was calculated from the total number of tests and the length of use.

Each alert was classified as either an unreliable pattern or test score change. Unreliable pattern alerts have been defined by the manufacturer as occuring when a patient consistently over-responds (marking locations far away from light projection) or under-responds (ignoring light projections completely) during testing after a period of reliable results. Test score change alerts have been defined by the manufacturer as occurring when a patient incorrectly marks locations of distortion on the light projections. Both types of alerts may be indicative of CNV onset.[@bib34] ^,^ [@bib36] For each alert, the frequency of use in the month before the alert was also captured. Two frequencies of use were calculated to investigate compliance: "adequate" frequency was defined by the HOME study at ≥2 tests per week; "instructed" frequency was defined at ≥3 tests per week as specified by the manufacturer to patients. In a pre-determined subset of the population (all patients managed at Retina Consultants of Houston, Houston, TX), a granular analysis was performed by chart review to assess the clinical value of home monitoring with this device; additional clinical information regarding disease state, development of nAMD and follow-up appointments was collected. In this subpopulation, each alert was classified as positive or false-positive. A false-positive was defined as a test score change alert that did not result in a diagnosis of CNV at the following clinic appointment. Clinical conversions to nAMD that were not identified by ForeseeHome during active device usage were classified as false-negative conversions. Diagnoses following alerts were confirmed with spectral-domain optical coherence tomography (OCT) and clinical examination and, if clinically warranted, fluorescein angiography (FA). FA was not performed for all patients who experienced an alert.

Methods of Analysis {#sec3}
===================

Data was analyzed using two methods: eye-level data and patient-level data. Eye-level data considered each eye of each patient separately. Patient-level data was used for age correlation. For patients with both eyes prescribed for ForeseeHome use, the patient was categorized as "established baseline" if at least one eye was able to establish baseline.

Statistical comparisons were performed using RStudio version 1.2.5019 ([www.rstudio.com](http://www.rstudio.com/){#intref0020}). The Shapiro-Wilk test was used to test for normality among the data set. Statistical significance of means was measured using either parametric Student's t-test or non-parametric Wilcoxon tests when appropriate. Differences between sites were analyzed using the following metrics: proportion of eyes that never used the device, proportion of eyes that could not establish initial baseline, mean frequency of use, mean age, proportion of subjects within the HOME study age range, proportion of subjects within the HOME study VA range, and proportion of OD study eyes. Chi square tests were performed to test for significant differences among proportions and 1-way analysis of variance (ANOVA) was used to test for significant differences among mean values. A p-value less than 0.05 was considered statistically significant and a t-test distribution was used to calculate 95% confidence intervals (CI).

Results {#sec4}
=======

Initial Baseline {#sec4.1}
----------------

Among the four retina practices evaluated, 775 eyes of 448 patients were prescribed use of the ForeseeHome device. 126 eyes (16.3%) never used the device after prescription. In total, among eyes that attempted to establish a baseline, 478 eyes (73.7%) were able to establish baseline and 171 eyes (26.3%) were not successful at establishing a baseline ([Figure 1](#fig1){ref-type="fig"} ). Among the patients who used the device at least once, baseline demographics are summarized in [Table 1](#tbl1){ref-type="table"} . Among the analyzed factors, the proportion of eyes that never used the device was found to be statistically significantly different between the sites (p=0.0001); all other comparisons were not statistically significantly different. Upon prescription of the device, 441 patients (98.4%) had documented medical insurance; 402 patients (89.7%) had Medicare, 35 patients (7.8%) had commercial insurance, and 4 patients (\<1%) had other insurance. At first usage, the mean age of patients who used the device was 76.2±8.4 years. The mean ages of patients who could vs could not establish a baseline were 75.1±7.8 vs 80.5±9.2 years (p\<0.001; Wilcoxon rank-sum).FIGURE 1Diagram illustrating usage of the ForeseeHome device for all prescribed eyes.Table 1Subject Demographics\*TotalSite 1Site 2Site 3Site 4**Patients, n (%)**37846 (12.2)23 (6.1)112 (29.6)197 (52.1)**Age, mean (SD)**76.2 (8.4)75.5 (7.4)76.8 (6.7)75.9 (6.3)76.6 (9.7)**53 to 90 yrs, n (%)\*\***361 (95.5)46 (100)22 (95.7)110 (98.2)183 (92.9)**Female, n (%)**236 (62.4)30 (65.2)17 (73.9)66 (58.9)124 (62.4)**Eyes, n (%)**64969 (10.6)42 (6.5)192 (29.6)346 (53.3)**OD, n (%)**325 (50.1)33 (47.8)20 (52.6)101 (52.6)171 (49.4)**VA 20/60 or better, n (%)\*\***616 (94.9)64 (92.7)40 (95.2)185 (96.4)327 (94.5)[^1][^2]

Longitudinal Activity {#sec4.2}
---------------------

Among eyes that established a baseline, mean frequency of use over the entire length of use through the end of the current study period, was 3.44±1.86 tests per week; 126 (26.4%) and 250 (52.3%) of eyes had an overall frequency of use \<2 and \<3 tests per week ([Figure 2](#fig2){ref-type="fig"} ). Among this population that established a baseline, the proportion of eyes that continued to be active longitudinally was calculated. Discontinuation of the device was most common within the first year of use: 24.7% of eyes stopped usage within the first year, 36.6% stopped within 2 years and 52.3% stopped within 3 years ([Figure 3](#fig3){ref-type="fig"} ). More specifically by year, among eyes with the potential to have been tested for ≥1 year, 24.7% stopped before 1 year; among eyes with the potential to have been tested for ≥2 years, 13.8% stopped between 1 and 2 years; among eyes with the potential to have been tested for ≥3 years, 13.8% stopped between years 2 and 3.FIGURE 2Overall frequency of use of the ForeseeHome device for eyes that established initial baseline. Frequency of use was calculated as tests per week and an inadequate frequency of use was set at \<2 tests per week. Upon prescription, the manufacturer also instructs patients to use the device more than 3 times per week. Among this population, 126 (26.4%) and 250 (52.3%) of eyes had an overall frequency of \<2 or \<3 tests per week.FIGURE 3Graph illustrating the length of use of the ForeseeHome device by eyes that established baseline. Data table with the corresponding number and percentage of active patients every three months of use is included at the bottom.

Alerts {#sec4.3}
------

Through a mean of 20.35 months of potential total time on the device, 106 eyes (22.2% of eyes that established baseline) experienced at least one alert and cumulatively, there were a total of 152 alerts recorded. Through 6, 12, 24 and 36 months of device usage, 9.1%, 14.1%, 15.9% and 17.3% of active eyes had at least one alert, cumulatively. 125 (82.2%) alerts were categorized as test score change alerts and 27 (17.8%) alerts were categorized as unreliable pattern alerts. For each alert, the ForeseeHome portal reported on the frequency of use in the month directly before the alert; 22 (14.4%) and 52 alerts (33.5%) had an overall frequency of use \<2 and \<3 tests per week in the month before alert. Of the 106 eyes that had at least one alert, 44 (41.5%) could not re-establish a baseline following an alert.

Clinical Utility {#sec4.4}
----------------

In a pre-determined subset of eyes from one clinical site, additional analyses of associated clinical information and conversion to nAMD was performed ([Figure 4](#fig4){ref-type="fig"} ). All of the following data was collected from this pre-determined subset. Of 211 eyes prescribed for 123 patients, 19 (9%) never used the device. Of the 192 (91%) that used the device at least once, over 95% met the ForeseeHome recommendations of VA 20/60 or better; a total of 18 (9.4%) subsequently converted from iAMD to nAMD over a mean of 8.44 months.FIGURE 4Diagram illustrating a granular analysis of a pre-specified subset of eyes. Red boxes indicate eyes that converted to nAMD.

56 (29.2%) eyes could not establish baseline with 7 of these eyes subsequently converting to nAMD. Of the 136 eyes (70.8%) that established a baseline, 99 (72.1%) had no alerts and 5 of these eyes subsequently developed nAMD without antecedent detection by the device. Among these 5 eyes, 3 conversions were detected during regularly scheduled follow-up appointments, and 2 were detected at appointments scheduled due to subjective change in vision that was noted by the patient. All 5 eyes presented with new evidence of exudative fluid on OCT evaluation, and 2 eyes had concurrent FA demonstrating the presence of new CNV. Overall frequency of use in these five eyes was 4.2±1.5 tests per week (range 2.7 to 6.3). The remaining 37 eyes (27.2%) experienced 52 alerts, with a mean of 1.4±0.64 alerts per eye over a mean of 15.0±7.5 months of follow-up. 43 (82.7%) of these alerts were categorized as test score change, and 9 (17.3%) were categorized as unreliable pattern alerts. 7 (14.6%) and 16 (33.3%) eyes had frequency of use \<2 and \<3 tests per week in the month before the alert, respectively. 35 (67.3%) alerts had clinic visits within 4 weeks of notification, with an average of 8.97 days between alert and follow-up.

Following an alert, each eye must re-establish a new baseline in order to continue usage of the device. Of the 37 eyes with alerts, 15 (40.5%) could not re-establish baseline with 3 of these eyes subsequently converting to nAMD after inactivation of device usage. Following test score change alerts, 3 eyes converted to nAMD with correct identification by ForeseeHome with confirmation at follow-up appointments 3, 18 and 27 days after the alert; 2 of these conversions were confirmed in pre-scheduled, standard-of-care follow-up appointments and 1 of these conversions was confirmed in a Foresee-specific follow-up appointment, 3 days after the alert. 19 eyes (51.4%) were able to re-establish baseline after alerts and continue usage of the device.

Overall, among eyes that established baseline, 47 (88.7%) alerts from 33 eyes were false-positives, resulting in a mean 1.42±0.61 false-positive alerts per eye over 1.12±0.59 device-usage years and 0.43 false alerts per year of device usage per patient; upon extrapolation, this would result in 1 false alert per patient every 2.33 years. 29 (87.9%) of these eyes did not develop CNV following false-positive alerts with a mean follow-up time of 12.4±6.8 months, and 4 (12.1%) eventually converted to nAMD a mean 8.1±3.8 months following their first false-positive alert. Following the first false-positive alert, eyes had a mean 5.7±4.8 appointments over a mean 11.9±6.6 months, resulting in a follow-up rate of 0.57 appointments per month or 1 appointment every 1.75 months until their last follow-up appointment or their conversion to nAMD. Among eyes with a fellow eye being treated for nAMD (n=7), the follow-up rate was 1 appointment every 1.55 months compared to 1 appointment every 1.83 months among eyes with a dry fellow eye (n=29). Additionally, among all eyes with false-positive alerts, 9 (27.3%) received at least one FA in the year following their first false-positive alert; 7 never developed CNV within the follow-up period and 2 converted within 5.1 and 6.75 months of the false-positive alert.

Discussion {#sec5}
==========

At-home telemonitoring is a validated method for monitoring disease states across multiple specialties including cardiology, pulmonology, obstetrics, and ophthalmology.[@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] ^,^ [@bib34] ^,^ [@bib35] Despite this, real-world usage of home monitoring devices can be challenging as evidenced by the current dataset.

The current retrospective study evaluated the clinical application of the ForeseeHome monitoring device among 775 eyes from 4 geographically distinct retina practices across the US. 83.7% of eyes used the device at least once and, among these, 26.3% were unable to establish initial baseline in order to begin monitoring. This challenge was evident in the HOME study with 15.9% of participants screen-failing due to pre-existing visual field defects with an additional 8% of randomized eyes reportedly being unable to establish baseline[@bib34] -- smaller proportions than observed in the current study. Multiple factors likely contributed to a larger proportion of eyes being unable to establish baseline in the current study, including an older mean age of the current population at 76.2±8.4 years compared to a mean age of 72.5±7.7 years in the HOME study.

Once a baseline is established, consistent, long-term use of the device is important to maximize the opportunity to prevent vision loss by early detection of conversion to nAMD. Among eyes that established baseline within the current analysis, approximately a quarter did not use the device with adequate frequency (≥2 tests per week) and approximately half were noncompliant with manufacturer instructions for frequency of use (≥3 tests per week). Among 125 patients experiencing test score change alerts, 13.6% had an inadequate frequency of use and 32% failed to use the device as frequently as instructed in the preceding month before the alert. Without an adequate testing frequency, the visual field data and alerts may be less reliable, decreasing the effectiveness of the device. Complete discontinuation of device usage was another hurdle; 25% of eyes stopped use of the device within 1 year, nearly 40% stopped within 2 years and over half stopped within 3 years. This discontinuation rate is higher than the 20% rate reported in the HOME study through a mean 1.4 years of follow-up.[@bib34] This discrepancy in compliance could be attributed to differences in the populations of the HOME study vs the current retrospective study. The HOME study was a prospective clinical trial including subjects who may have been more intrinsically motivated and encouraged by study staff to continue device usage; in contrast, the current study retrospectively investigated clinic patients who may not have been as motivated as patients who consent to participate in a clinical trial. Notably, the demographics of eyes that used the device at least once in the current real-world study appeared similar to those reported in the HOME study.

Issues related to patient compliance could have been influenced by several factors. For example, patients may not have had computer experience, making it difficult for them to operate the device or establish a baseline. Patients also may not have fully understood the importance of home telemonitoring and frequent device usage. In the current study, across all four clinics, it was standard for physicians to encourage continued and consistent usage of the ForeseeHome device at each visit. Additionally, patients received monthly reports from ForeseeHome describing their compliance in the past month with recommendations for minimum frequency of use. Issues of compliance may be able to be further improved by more thoroughly screening patients before prescription, ensuring that they would be able to effectively use the device and clinicians could further emphasize the importance of consistent testing and the benefit of early CNV detection on their visual outcomes.

The current study demonstrated a higher rate of false-positive alerts per patient per year than did the HOME study. The HOME study reported 0.24 false alerts per person per year, or 1 false alert per person every 4.2 years,[@bib34] compared to 1 false alert per person every 2.28 years in the current series. Preferred practice guidelines recommend follow-up visits for iAMD patients every 6-18 months.[@bib9] In the current study only 12.1% of eyes with false-positive alerts ever developed CNV following the alert, and eyes were followed clinically a mean of once every 1.75 months, much more frequent than the standard of care for iAMD patients, often related to fellow-eye management needs. Presumably, if these false-positive alerts were attributable to the device identifying CNV conversion earlier than OCT or ophthalmic examination were able, these lesions would be expected to grow and become clinically obvious with subsequent clinical visits.[@bib44]

Notably, data from the current study suggested a possible relationship between eyes unable to establish baseline and eventual conversion to nAMD. Among the subset of eyes analyzed for clinical utility of the device, 12.5% of eyes that could not establish initial baseline later converted to nAMD compared to 8.1% of eyes that could establish baseline. An additional 20% of eyes that were unable to re-establish baseline following a false-positive alert also subsequently converted to nAMD. Therefore, patients unable to establish baseline may indicate a subpopulation at higher risk of converting to nAMD, which may warrant more frequent follow-up visits. Further studies may be warranted to investigate this relationship.

Overall, the results of the current study highlight some of the challenges accompanying home monitoring.[@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] Telemonitoring strategies range from simple phone calls with health professionals to complex devices like ForeseeHome. Some monitors, like the Holter device and other cardiac monitors, collect data automatically and over short periods of time.[@bib37] ^,^ [@bib39] ^,^ [@bib42] These devices do not have some of the inherent compliance issues associated with long-term monitoring devices such as ForeseeHome, as patients do not have to manually input data for the monitoring to be effective, nor do they have to continue monitoring indefinitely. For devices in which patients are required to manually test themselves or input data periodically, ongoing self-motivation is required. Several studies evaluating such devices have described similar compliance challenges as identified in the current study with patient adherence decreasing over time.[@bib40] ^,^ [@bib41] ^,^ [@bib43]

Despite the challenges detailed in the current study, the ForeseeHome device remains an important, first-generation device that represents the invaluable potentially positive impact that home monitoring could have on improving long-term outcomes when managing not only AMD but a host of retinal diseases. The ongoing coronavirus disease 2019 (COVID-19) pandemic highlights the importance of advancing our ability to perform home monitoring in ophthalmology. Many ophthalmology clinics experienced a meaningful decrease in patient volume during this pandemic; at the University of Iowa, for example, patient volume decreased by 85%.[@bib45] For patients being monitored for conversion to nAMD, this potential for disruption of routine clinician assessment is concerning and could lead to worse visual outcomes for those who convert during this time due to delayed diagnosis. Current methods of home monitoring in ophthalmology including the Amsler grid and personal device applications such as smartphones and tablets face similar challenges with patient compliance, and also challenges related to reliable use and low-sensitivity for visual changes.[@bib33] ^,^ [@bib46] ^,^ [@bib47] Nevertheless, technology development is a continuous process, and next generation devices and new technologies such as incorporation of OCT[@bib48] ^,^ [@bib49] into home monitoring systems promise to improve upon the difficulties encountered with current technology and may ultimately transform the way patients are diagnosed and managed. An important trait of home OCT technology is that the assessment of meaningful change will be passive following patient initiation of the at-home test. This would eliminate the limitation of patient data entry from which ForeseeHome and many other home monitoring devices suffer. Finally, increased understanding of the reasoning behind patient noncompliance may help aid in the creation of optimal telemonitoring devices.

Strengths of the current study include a large data set from 4 geographically distinct retina centers across the USA. Further, granular data concerning conversion to nAMD in a subset representing 27% of the overall population provided important information on the clinical utility of the ForeseeHome device. Limitations of the study include that VA and other aspects of the disease state were not uniformly evaluated throughout the study and the follow-up time for device usage was limited per eye due to the retrospective nature of the study. The retrospective nature of the study also made it difficult to evaluate how compliance with device usage was encouraged by physicians and staff longitudinally. It is also unknown how thoroughly patients were pre-screened before prescription of the device for their ability to use a computer mouse. The cost of the device for each patient was also not assessed and the influence of cost could not be evaluated. Additionally, eyes that were classified as "never used" did not distinguish whether patients had never filled their prescription or filled their prescription and never used the device. The current study was also limited in its follow-up of test score change alerts and its confirmation of dry AMD or nAMD diagnosis; in the HOME study, every alert was followed up with clinical examination, FA and OCT while the current study only followed up alerts with OCT and clinical examination with FA being performed only if deemed clinically indicated. Finally, the current study did not evaluate possible reasons for false-positive alerts such as structural changes in eyes not due to CNV development.

In summary, the current study investigated the utility of the ForeseeHome device in routine clinical practice. Compared to results from the HOME trial, patient compliance and ability to use the device were more limited, as clinically meaningful proportions of patients never used the device or were unable to establish a baseline. Continuous usage of the device was low and decreased over time, and the overall false-positive rate was 93.2%, a higher rate than reported in the HOME trial. These results underscore a need for further refinement of the technologies employed for home monitoring for the conversation of iAMD to nAMD with the goal of optimizing long-term visual outcomes for patients.
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Précis

Real-world analysis of telemonitoring with ForeseeHome for intermediate age-related macular degeneration (iAMD) resulted in limited patient adherence and overall modest clinical utility, demonstrating a need for further improvement in home monitoring technology for iAMD.

[^1]: \*This table describes the demographic distribution of those who used the device at least once

[^2]: \*\*Subjects in the HOME study were required to be between 53 to 90 years old with a VA 20/60 or better
